<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-weight: bold;">As filed with the Securities and Exchange Commission on December 3, 2020</div>
    <div style="text-align: right; font-weight: bold;">Registration No. 333-</div>
    <div>
      <div>
        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: italic; font-weight: bold;">UNDER</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;">KINNATE BIOPHARMA INC.</div>
    <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za0fdd6dc816c4c5ab51435d77300f68f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Delaware</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">82-4566526</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of</div>
            <div style="text-align: center; font-weight: bold;">incorporation or organization)</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(I.R.S. Employer</div>
            <div style="text-align: center; font-weight: bold;">Identification Number)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">11975 El Camino Real, Suite 101</div>
    <div style="text-align: center; font-weight: bold;">San Diego, CA 92130</div>
    <div style="text-align: center; font-weight: bold;">(858) 299-4699</div>
    <div style="text-align: center; font-weight: bold;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-weight: bold;">2020 Equity Incentive Plan</div>
    <div style="text-align: center; font-weight: bold;">2020 Employee Stock Purchase Plan</div>
    <div style="text-align: center; font-weight: bold;">2018 Equity Incentive Plan</div>
    <div style="text-align: center; font-weight: bold;">(Full title of the plan)</div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-weight: bold;">Nima Farzan</div>
    <div style="text-align: center; font-weight: bold;">President and Chief Executive Officer</div>
    <div style="text-align: center; font-weight: bold;">Kinnate Biopharma Inc.</div>
    <div style="text-align: center; font-weight: bold;">11975 El Camino Real, Suite 101</div>
    <div style="text-align: center; font-weight: bold;">San Diego, CA 92130</div>
    <div style="text-align: center; font-weight: bold;">(858) 299-4699</div>
    <div style="text-align: center; font-weight: bold;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-style: italic;">Copies to:</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf6a0eab2532d440e89229bd64e72cb6c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Tony Jeffries</div>
            <div style="text-align: center; font-weight: bold;">Miranda Biven</div>
            <div style="text-align: center; font-weight: bold;">Jennifer Knapp</div>
            <div style="text-align: center; font-weight: bold;">Wilson Sonsini Goodrich &amp; Rosati</div>
            <div style="text-align: center; font-weight: bold;">Professional Corporation</div>
            <div style="text-align: center; font-weight: bold;">650 Page Mill Road</div>
            <div style="text-align: center; font-weight: bold;">Palo Alto, CA 94304</div>
            <div style="text-align: center; font-weight: bold;">(650) 493-9300</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Mark Meltz</div>
            <div style="text-align: center; font-weight: bold;">Chief Operating Officer and General Counsel</div>
            <div style="text-align: center; font-weight: bold;">Kinnate Biopharma Inc.</div>
            <div style="text-align: center; font-weight: bold;">11975 El Camino Real, Suite 101</div>
            <div style="text-align: center; font-weight: bold;">San Diego, CA 92130</div>
            <div style="text-align: center; font-weight: bold;">(858) 299-4699</div>
          </td>
        </tr>

    </table>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated
      filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z2d053f186ab04099ab8d4be91aa0fc98" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 20%; vertical-align: bottom;">
            <div>Large accelerated filer</div>
          </td>
          <td style="width: 40%; vertical-align: bottom;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
          </td>
          <td style="width: 29.55%; vertical-align: bottom;">
            <div>Accelerated filer</div>
          </td>
          <td style="width: 10%; vertical-align: bottom;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: bottom;">
            <div>Non-accelerated filer</div>
          </td>
          <td style="width: 40%; vertical-align: bottom;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
          <td style="width: 29.55%; vertical-align: bottom;">
            <div>Smaller reporting company</div>
          </td>
          <td style="width: 10%; vertical-align: bottom;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: bottom;">&#160;</td>
          <td style="width: 40%; vertical-align: bottom;">&#160;</td>
          <td style="width: 29.55%; vertical-align: bottom;">
            <div>Emerging growth company</div>
          </td>
          <td style="width: 10%; vertical-align: bottom;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; margin-left: 1.35pt; font-weight: bold;">CALCULATION OF REGISTRATION FEE</div>
    <table id="za8fa41c5dc644ebaa9ce0794563a44a8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" cellpadding="0" cellspacing="0">

        <tr>
          <td rowspan="1" style="vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">&#160;</td>
          <td rowspan="1" colspan="1" style="border-left: medium none rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td rowspan="1" colspan="2" style="vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td rowspan="1" colspan="1" style="vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td rowspan="1" colspan="1" style="border-left: medium none rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td rowspan="1" colspan="2" style="vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td rowspan="1" colspan="1" style="vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td rowspan="1" colspan="1" style="border-left: medium none rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td rowspan="1" colspan="2" style="vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td rowspan="1" colspan="1" style="vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td rowspan="1" colspan="1" style="border-left: medium none rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td rowspan="1" colspan="2" style="vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td rowspan="1" colspan="1" style="vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Title of Securities</div>
            <div style="text-align: center; font-weight: bold;">to be Registered</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Amount</div>
            <div style="text-align: center; font-weight: bold;">to be</div>
            <div style="text-align: center; font-weight: bold;">Registered<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Proposed</div>
            <div style="text-align: center; font-weight: bold;">Maximum</div>
            <div style="text-align: center; font-weight: bold;">Offering Price</div>
            <div style="text-align: center; font-weight: bold;">Per Share</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Proposed</div>
            <div style="text-align: center; font-weight: bold;">Maximum</div>
            <div style="text-align: center; font-weight: bold;">Aggregate</div>
            <div style="text-align: center; font-weight: bold;">Offering Price</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div style="text-align: center; font-weight: bold;">Amount of</div>
            <div style="text-align: center; font-weight: bold;">Registration Fee</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
            <div style="margin-left: 12pt;">Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2020 Equity Incentive Plan</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>5,806,039</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup>&#160;</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>20.00</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup>&#160;</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>116,120,780<br>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>12,669<br>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 52%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
            <div style="margin-left: 12pt;">Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2020 Employee Stock Purchase Plan</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>435,000</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup>&#160;</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>17.00</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup>&#160;</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>7,395,000<br>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>807<br>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
            <div style="margin-left: 12pt;">Common Stock, $0.0001 par value per share, reserved for issuance pursuant to options outstanding under the 2018 Equity Incentive Plan</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>6,080,966</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup>&#160;</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>3.63</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(</sup><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"><font style="vertical-align: text-top; line-height: 1;"></font>7</sup><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">)</sup>&#160;</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>22,073,907</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" nowrap="nowrap" valign="bottom">
            <div>2,409</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 52%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
            <div style="margin-left: 12pt;">TOTAL:</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>12,322,005</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>145,589,687<br>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">
            <div>15,885<br>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap" valign="bottom">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0e848b4509424e398eccebc398ab2b9f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: -0.05pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this Registration Statement shall also cover any additional shares of the Registrant&#8217;s common stock that become issuable under the 2020 Equity
              Incentive Plan (the&#160; &#8220;2020 Plan&#8221;), the 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) and the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) by reason of any stock dividend, stock split, recapitalization or other similar transaction
              effected without receipt of consideration that increases the number of the Registrant&#8217;s outstanding shares of common stock.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd9368a769d5a4946a11868e8f439830f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: -0.05pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Represents 5,806,039 shares of common stock reserved for issuance under the 2020 Plan as of the date of this Registration Statement, which includes 5,218,000 shares approved for issuance under the 2020 Plan plus 588,039 shares of common
              stock that were reserved but not issued pursuant to awards granted under the 2018 Plan that are not subject to any awards granted thereunder.&#160; As of the date hereof, 121,503 shares of common stock are subject to options outstanding under the
              2020 Plan. The number of shares of common stock available under the 2020 Plan will be increased by any shares of common stock subject to awards outstanding under the 2018 Plan, that on or after the effectiveness of the 2020 Plan, expire or
              otherwise terminate without having been exercised in full, are tendered to or withheld by the Registrant for payment of an exercise price or for tax withholding obligations, or are forfeited to or repurchased by the Registrant due to failure
              to vest.&#160; The maximum number of shares that can be added to the 2020 Plan from the 2018 Plan is 6,669,017. See footnote 6 below.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7049b2cb7ebe4e6184b1da62e6799fa0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: -0.05pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $20.00 per share, which is the initial public offering price set forth on the cover page of the Registrant&#8217;s Prospectus
              dated December 2, 2020 relating to its initial public offering.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7705e2fd01bc4ee9918defcc807a359d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: -0.05pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">(4)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Represents 435,000 shares of common stock reserved for issuance under the 2020 ESPP.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z998dc04374c0476494325faf2ff3ed15" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: -0.05pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">(5)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of 85% of $20.00, which is the initial public offering price set forth on the cover page of the Registrant&#8217;s Prospectus dated
              December 2, 2020 relating to its initial public offering. Pursuant to the 2020 ESPP, the purchase price of the shares of common stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the common stock on
              (i) the first trading day of the offering period or (ii) the exercise date.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z63ebb8dc43c24ef2ab139317265789fb" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: -0.05pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">(6)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Represents 6,080,966 shares of common stock reserved for issuance pursuant to options outstanding under the 2018 Plan as of the date of this Registration Statement.&#160; To the extent that, on or after the effectiveness of the 2020 Plan, any
              shares subject to awards under the 2018 Plan expire or otherwise terminate without having been exercised or issued in full, are tendered to or withheld by the Registrant for payment of an exercise price or tax withholding obligations, or are
              forfeited to or repurchased by the Registrant due to failure vest, the shares of common stock subject to such awards will become available for issuance under the 2020 Plan.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z462e619f236b49239cb663bf3b82fe6a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: -0.05pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">(7)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $3.63, the weighted average price per share of outstanding stock option awards under the 2018 Plan as of December 3, 2020.</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">PART I</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE PROSPECTUS</div>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (this &#8220;Registration Statement&#8221;) in accordance with the provisions of Rule 428 under the
      Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as
      specified by Rule 428(b)(1) under the Securities Act.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">PART II</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN REGISTRATION STATEMENT</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z130982e1fb174961ad2e2c049eeee84a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 48.95pt; vertical-align: top; align: right; font-weight: bold;">Item 3.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Incorporation of Documents by Reference.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">Kinnate Biopharma Inc. (the &#8220;Registrant&#8221;) hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;):</div>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">(1) The Registrant&#8217;s Prospectus dated December 2, 2020, filed with the Commission on December 3, 2020 pursuant to Rule 424(b) under the Securities Act, relating to the Registration Statement on Form S-1, as amended
      (File No. 333-250086), which contains the Registrant&#8217;s audited financial statements for the latest fiscal year for which such statements have been filed; and</div>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">(2) The description of the Registrant&#8217;s Common Stock contained in the Company&#8217;s Registration Statement on Form 8-A (File No 001-39743) filed with the Commission on November 30, 2020, pursuant to Section 12(b) of the
      Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), including any amendment or report filed for the purpose of updating such description.</div>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to
      this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from
      the date of filing of such documents; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that documents or information deemed to have been furnished and not filed in accordance with the rules of the
      Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
      of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or
      superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z23e00e54635747a786dd735b6a3f9701" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 48.95pt; vertical-align: top; align: right; font-weight: bold;">Item 4.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Description of Securities.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">Not applicable.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z746c4db464f148cab9378556be8f4ae2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 48.95pt; vertical-align: top; align: right; font-weight: bold;">Item 5.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Interests of Named Experts and Counsel.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">Not applicable.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc7358fd4a1cb4852abdf04b2f80f69b4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 48.95pt; vertical-align: top; align: right; font-weight: bold;">Item 6.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Indemnification of Directors and Officers.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">Section 145 of the Delaware General Corporation Law empowers a corporation to indemnify its directors and officers and to purchase insurance with respect to liability arising out of their capacity or status as
      directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed to be in our best interests, and, with respect to any criminal action, had no reasonable cause to believe the person&#8217;s actions were
      unlawful. The Delaware General Corporation Law further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation&#8217;s bylaws, any
      agreement, a vote of stockholders or otherwise. The certificate of incorporation of the registrant to be in effect upon the completion of this offering provides for the indemnification of the registrant&#8217;s directors and officers to the fullest extent
      permitted under the Delaware General Corporation Law. In addition, the bylaws of the registrant to be in effect upon the completion of this offering require the registrant to fully indemnify any person who was or is a party or is threatened to be
      made a party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was a director or officer of the registrant, or is or was a
      director or officer of the registrant serving at the registrant&#8217;s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney&#8217;s fees),
      judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, to the fullest extent permitted by applicable law.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-indent: 48.95pt;">Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or
      its stockholders for monetary damages for breach of fiduciary duty as a director, except (1) for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve
      intentional misconduct or a knowing violation of law, (3) for payments of unlawful dividends or unlawful stock repurchases or redemptions or (4) for any transaction from which the director derived an improper personal benefit. The registrant&#8217;s
      certificate of incorporation to be in effect upon the completion of this offering provides that the registrant&#8217;s directors shall not be personally liable to it or its stockholders for monetary damages for breach of fiduciary duty as a director and
      that if the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the registrant&#8217;s directors shall be eliminated or limited to the fullest
      extent permitted by the Delaware General Corporation Law, as so amended.</div>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">Section 174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption
      may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes
      of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.</div>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">As permitted by the Delaware General Corporation Law, the registrant has entered into separate indemnification agreements with each of the registrant&#8217;s directors and executive officers which would require the
      registrant, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors or executive officers.</div>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">The registrant expects to obtain and maintain insurance policies under which its directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in
      connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided by these policies
      may apply whether or not the registrant would have the power to indemnify such person against such liability under the provisions of the Delaware General Corporation Law.</div>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">These indemnification provisions and the indemnification agreements entered into between the registrant and the registrant&#8217;s officers and directors may be sufficiently broad to permit indemnification of the
      registrant&#8217;s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act of 1933, as amended.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0d8c4c39e937405c8f1f41f2e0139586" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 48.95pt; vertical-align: top; align: right; font-weight: bold;">Item 7.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Exemption from Registration Claimed.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: 48.95pt;">Not applicable.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfe09ee4b0a444491aaa8eb6c1bbce404" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 48.95pt; vertical-align: top; align: right; font-weight: bold;">Item 8.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Exhibits.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7b2fa50d54724e2ab0d8d5311189d8de" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td style="width: 55%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td colspan="4" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Incorporated by Reference</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="font-weight: bold;">Exhibit</div>
            <div style="font-weight: bold;">Number</div>
          </td>
          <td style="width: 55%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Description</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">Form</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">File No.</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">Exhibit</div>
          </td>
          <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="font-weight: bold;">Filing Date</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9%; vertical-align: top;">
            <div>&#160; <a href="https://www.sec.gov/Archives/edgar/data/1797768/000114036120026755/nt10013659x9_ex4-2.htm">4.2</a></div>
          </td>
          <td style="width: 55%; vertical-align: bottom;">
            <div style="text-indent: -5.85pt; margin-left: 12pt;">Specimen common stock certificate of the Registrant</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: center;">S-1/A</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: right; margin-left: 6.75pt;">333-250086</div>
          </td>
          <td style="width: 9%; vertical-align: top; text-align: right;" nowrap="nowrap">
            <div style="font-family: 'Times New Roman',Times,serif;">4.2</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: right; margin-left: 1.55pt;">11/30/2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9%; vertical-align: top;">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1797768/000114036120025527/nt10013659x6_ex10-2.htm">10.1</a></div>
          </td>
          <td style="width: 55%; vertical-align: bottom;">
            <div style="text-indent: -5.85pt; margin-left: 12pt;">2018 Equity Incentive Plan, as amended, and form agreement thereunder</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: center;">S-1</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: right; margin-left: 6.75pt;">333-250086</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: right;">10.2</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: right; margin-left: 1.55pt;">11/13/2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9%; vertical-align: top;">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1797768/000114036120026755/nt10013659x9_ex10-3.htm">10.2</a></div>
          </td>
          <td style="width: 55%; vertical-align: bottom;">
            <div style="text-indent: -5.85pt; margin-left: 12pt;">2020 Equity Incentive Plan, and form agreements thereunder</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: center;">S-1/A</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: right; margin-left: 6.75pt;">333-250086</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: right;">10.3</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: right; margin-left: 1.55pt;">11/30/2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9%; vertical-align: top;">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1797768/000114036120026755/nt10013659x9_ex10-4.htm">10.3</a></div>
          </td>
          <td style="width: 55%; vertical-align: bottom;">
            <div style="text-indent: -5.85pt; margin-left: 12pt;">2020 Employee Stock Purchase Plan and form agreements thereunder</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: center;">S-1/A</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: right; margin-left: 6.75pt;">333-250086</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: right;">10.4</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;" nowrap="nowrap">
            <div style="text-align: right; margin-left: 1.55pt;">11/30/2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9%; vertical-align: top;">
            <div>&#160;<a href="nt10013659x14_ex5-1.htm"> 5.1</a>*</div>
          </td>
          <td style="width: 55%; vertical-align: bottom;">
            <div style="text-indent: -5.85pt; margin-left: 12pt;">Opinion of Wilson Sonsini Goodrich &amp; Rosati, Professional Corporation</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 9%; vertical-align: top;">
            <div><a href="nt10013659x14_ex23-1.htm">23.1</a>*</div>
          </td>
          <td style="width: 55%; vertical-align: bottom;">
            <div style="text-indent: -5.85pt; margin-left: 12pt;">Consent of Independent Registered Public Accounting Firm</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 9%; vertical-align: top;">
            <div><a href="nt10013659x14_ex5-1.htm">23.2</a>*</div>
          </td>
          <td style="width: 55%; vertical-align: bottom;">
            <div style="text-indent: -5.85pt; margin-left: 12pt;">Consent of Wilson Sonsini Goodrich &amp; Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 9%; vertical-align: top;">
            <div><a href="#SIGNATURES">24.1</a>*</div>
          </td>
          <td style="width: 55%; vertical-align: bottom;">
            <div style="text-indent: -5.85pt; margin-left: 12pt;">Power of Attorney (contained on signature page hereto)</div>
          </td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div>
      <div> <br>
      </div>
      <div>*Filed herewith.</div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z58feb2a6be41459e9a87e90dbc080e1a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 48.95pt; vertical-align: top; align: right; font-weight: bold;">Item 9.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Undertakings.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ef603b9a8bd4f56a379bc115ef5dce2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: -0.05pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">A.</td>
          <td style="width: auto; vertical-align: top;">
            <div>The undersigned Registrant hereby undertakes that:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z62be66a8bc374dc2a85888b02ab42aa1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 24.45pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top;">
            <div>It will file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z50e79711fa6a474e8b6835b7963ea663" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 49.5pt;"><br>
          </td>
          <td style="width: 26.1pt; vertical-align: top; align: right;">(i)</td>
          <td style="width: auto; vertical-align: top;">
            <div>To include any prospectus required by Section 10(a)(3) of the Securities Act;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3585c9a3347d4fe5a05d67bc3035641d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 49.5pt;"><br>
          </td>
          <td style="width: 26.1pt; vertical-align: top; align: right;">(ii)</td>
          <td style="width: auto; vertical-align: top;">
            <div>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
              in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered)
              and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no
              more than a 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z04862e450a2747c38f531755d40f6042" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 49.5pt;"><br>
          </td>
          <td style="width: 26.1pt; vertical-align: top; align: right;">(iii)</td>
          <td style="width: auto; vertical-align: top;">
            <div>To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><font style="font-style: italic;">Provided, however</font>, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed
      with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z966919505c134de48fe22ec22333f07e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 24.45pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top;">
            <div>For the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
              that time shall be deemed to be the initial bona fide offering thereof.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9dae5ab082dd4dfe95b3498128461a8d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 24.45pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top;">
            <div>It will remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z83e4f4ebe0d949c3bf3b8660dfac9822" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: -0.05pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">B.</td>
          <td style="width: auto; vertical-align: top;">
            <div>The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where
              applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to
              the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z00f7e916cb79412089f2645ede345bf3" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: -0.05pt;"><br>
          </td>
          <td style="width: 24.5pt; vertical-align: top; align: right;">C.</td>
          <td style="width: auto; vertical-align: top;">
            <div>Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions referenced in Item 6 of this Registration Statement,
              or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a
              claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or
              proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
              precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES<a name="SIGNATURES"><!--Anchor--></a></div>
    <div><br>
    </div>
    <div>Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement
      to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California, on the 3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> day of December, 2020.</div>
    <div> <br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z78a201a4652a49c781d85d6b57d862dd" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top;">
            <div style="font-weight: bold;">KINNATE BIOPHARMA INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: middle;">&#160;</td>
          <td style="width: 45%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div>By:</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div>/s/ Nima Farzan</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom;">
            <div>Nima Farzan</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom;">
            <div>President and Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">POWER OF ATTORNEY</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div>KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Nima Farzan and Mark Meltz, and each of them, as such individual&#8217;s true and lawful attorney in fact and agent with full power of
      substitution, for such individual in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in
      connection therewith, with the Securities and Exchange Commission, granting unto said attorney in fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
      therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney in fact, proxy and agent, or the individual&#8217;s substitute, may lawfully do or cause to be done by virtue
      hereof.</div>
    <div><br>
    </div>
    <div>Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze2c8fbf3d54d4035b9a4564a9c6c0c89" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 35.74%; vertical-align: bottom; border-bottom: #000000 2px solid;" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">Signature</div>
          </td>
          <td style="width: 32.64%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-weight: bold;">Title</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-weight: bold;">Date</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: middle; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 32.64%; vertical-align: top;">&#160;</td>
          <td style="width: 31.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div>/s/ Nima Farzan</div>
            </div>
          </td>
          <td rowspan="2" style="width: 32.64%; vertical-align: top;">
            <div>President, Chief Executive Officer and Director <font style="font-style: italic;">(Principal Executive Officer)</font></div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">
            <div>December 3, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top;">
            <div>Nima Farzan</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: middle;">&#160;</td>
          <td style="width: 32.64%; vertical-align: top;">&#160;</td>
          <td style="width: 31.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: bottom; border-bottom: 2px solid #000000;">
            <div>
              <div>/s/ Mark Meltz</div>
            </div>
          </td>
          <td rowspan="2" style="width: 32.64%; vertical-align: bottom;">
            <div>Chief Operating Officer and General Counsel <font style="font-style: italic;">(Principal Financial and Accounting Officer)</font></div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">
            <div>December 3, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top;">
            <div>Mark Meltz</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: middle;">&#160;</td>
          <td style="width: 32.64%; vertical-align: top;">&#160;</td>
          <td style="width: 31.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div>/s/ Dean Mitchell</div>
            </div>
          </td>
          <td rowspan="2" style="width: 32.64%; vertical-align: middle;">
            <div>Chair of the Board</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">
            <div>December 3, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top;">
            <div>Dean Mitchell</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: middle;">&#160;</td>
          <td style="width: 32.64%; vertical-align: top;">&#160;</td>
          <td style="width: 31.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div>/s/ Melisa Epperly</div>
            </div>
          </td>
          <td rowspan="2" style="width: 32.64%; vertical-align: middle;">
            <div>Director</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">
            <div>December 3, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top;">
            <div>Melissa Epperly</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: middle;">&#160;</td>
          <td style="width: 32.64%; vertical-align: top;">&#160;</td>
          <td style="width: 31.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div>/s/ Keith Flaherty, M.D.</div>
            </div>
          </td>
          <td rowspan="2" style="width: 32.64%; vertical-align: middle;">
            <div>Director</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">
            <div>December 3, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top;">
            <div>Keith Flaherty, M.D.</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: middle;">&#160;</td>
          <td style="width: 32.64%; vertical-align: top;">&#160;</td>
          <td style="width: 31.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div>/s/ Carl Gordon, Ph.D.</div>
            </div>
          </td>
          <td rowspan="2" style="width: 32.64%; vertical-align: middle;">
            <div>Director</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">
            <div>December 3, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top;">
            <div>Carl Gordon, Ph.D.</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: middle;">&#160;</td>
          <td style="width: 32.64%; vertical-align: top;">&#160;</td>
          <td style="width: 31.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div>/s/ Stephen Kaldor, Ph.D.</div>
            </div>
          </td>
          <td rowspan="2" style="width: 32.64%; vertical-align: middle;">
            <div>Director</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">
            <div>December 3, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top;">
            <div>Stephen Kaldor, Ph.D.</div>
          </td>
          <td style="width: 31.62%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: middle;">&#160;</td>
          <td style="width: 32.64%; vertical-align: top;">&#160;</td>
          <td style="width: 31.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div>/s/ Michael Rome, Ph.D.</div>
            </div>
          </td>
          <td rowspan="2" style="width: 32.64%; vertical-align: middle;">
            <div>Director</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">
            <div>December 3, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top;">
            <div>Michael Rome, Ph.D.</div>
          </td>
          <td style="width: 31.62%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: middle;">&#160;</td>
          <td style="width: 32.64%; vertical-align: top;">&#160;</td>
          <td style="width: 31.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div>/s/ Laurie Smaldone Alsup, M.D.</div>
            </div>
          </td>
          <td rowspan="2" style="width: 32.64%; vertical-align: middle;">
            <div>Director</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">
            <div>December 3, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top;">
            <div>Laurie Smaldone Alsup, M.D.</div>
          </td>
          <td style="width: 31.62%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: middle;">&#160;</td>
          <td style="width: 32.64%; vertical-align: top;">&#160;</td>
          <td style="width: 31.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top; border-bottom: 2px solid #000000;">
            <div>
              <div>/s/ Jim Tananbaum, M.D.</div>
            </div>
          </td>
          <td rowspan="2" style="width: 32.64%; vertical-align: middle;">
            <div>Director</div>
          </td>
          <td style="width: 31.62%; vertical-align: bottom;">
            <div>December 3, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35.74%; vertical-align: top;">
            <div>Jim Tananbaum M.D.</div>
          </td>
          <td style="width: 31.62%; vertical-align: middle;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "nt10013659x14_s8.htm", "description": "FORM S-8", "secsgml_size_bytes": 86381}]
{"company-data": {"conformed-name": "Kinnate Biopharma Inc.", "cik": "0001797768", "assigned-sic": "2834", "irs-number": "824566526", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-251105", "film-number": "201367607"}, "business-address": {"street1": "11975 EL CAMINO REAL, STE 101", "city": "SAN DIEGO", "state": "CA", "zip": "92130", "phone": "8582994699"}, "mail-address": {"street1": "11975 EL CAMINO REAL, STE 101", "city": "SAN DIEGO", "state": "CA", "zip": "92130"}}
As filed with the Securities and Exchange Commission on December 3, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
KINNATE BIOPHARMA INC.
(Exact name of registrant as specified in its charter)
Delaware
82-4566526
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
11975 El Camino Real, Suite 101
San Diego, CA 92130
(858) 299-4699
(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)
2020 Equity Incentive Plan
2020 Employee Stock Purchase Plan
2018 Equity Incentive Plan
(Full title of the plan)
Nima Farzan
President and Chief Executive Officer
Kinnate Biopharma Inc.
11975 El Camino Real, Suite 101
San Diego, CA 92130
(858) 299-4699
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Tony Jeffries
Miranda Biven
Jennifer Knapp
Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, CA 94304
(650) 493-9300
Mark Meltz
Chief Operating Officer and General Counsel
Kinnate Biopharma Inc.
11975 El Camino Real, Suite 101
San Diego, CA 92130
(858) 299-4699
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated
      filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act.
☐
CALCULATION OF REGISTRATION FEE
Title of Securities
to be Registered
Amount
to be
Registered
(1)
Proposed
Maximum
Offering Price
Per Share
Proposed
Maximum
Aggregate
Offering Price
Amount of
Registration Fee
Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2020 Equity Incentive Plan
5,806,039
(2)
$
20.00
(3)
$
116,120,780
$
12,669
Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2020 Employee Stock Purchase Plan
435,000
(4)
$
17.00
(5)
$
7,395,000
$
807
Common Stock, $0.0001 par value per share, reserved for issuance pursuant to options outstanding under the 2018 Equity Incentive Plan
6,080,966
(6)
$
3.63
(
7
)
$
22,073,907
$
2,409
TOTAL:
12,322,005
$
145,589,687
$
15,885
(1)
Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's common stock that become issuable under the 2020 Equity
              Incentive Plan (the  "2020 Plan"), the 2020 Employee Stock Purchase Plan (the "2020 ESPP") and the 2018 Equity Incentive Plan (the "2018 Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction
              effected without receipt of consideration that increases the number of the Registrant's outstanding shares of common stock.
(2)
Represents 5,806,039 shares of common stock reserved for issuance under the 2020 Plan as of the date of this Registration Statement, which includes 5,218,000 shares approved for issuance under the 2020 Plan plus 588,039 shares of common
              stock that were reserved but not issued pursuant to awards granted under the 2018 Plan that are not subject to any awards granted thereunder.  As of the date hereof, 121,503 shares of common stock are subject to options outstanding under the
              2020 Plan. The number of shares of common stock available under the 2020 Plan will be increased by any shares of common stock subject to awards outstanding under the 2018 Plan, that on or after the effectiveness of the 2020 Plan, expire or
              otherwise terminate without having been exercised in full, are tendered to or withheld by the Registrant for payment of an exercise price or for tax withholding obligations, or are forfeited to or repurchased by the Registrant due to failure
              to vest.  The maximum number of shares that can be added to the 2020 Plan from the 2018 Plan is 6,669,017. See footnote 6 below.
(3)
Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $20.00 per share, which is the initial public offering price set forth on the cover page of the Registrant's Prospectus
              dated December 2, 2020 relating to its initial public offering.
(4)
Represents 435,000 shares of common stock reserved for issuance under the 2020 ESPP.
(5)
Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of 85% of $20.00, which is the initial public offering price set forth on the cover page of the Registrant's Prospectus dated
              December 2, 2020 relating to its initial public offering. Pursuant to the 2020 ESPP, the purchase price of the shares of common stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the common stock on
              (i) the first trading day of the offering period or (ii) the exercise date.
(6)
Represents 6,080,966 shares of common stock reserved for issuance pursuant to options outstanding under the 2018 Plan as of the date of this Registration Statement.  To the extent that, on or after the effectiveness of the 2020 Plan, any
              shares subject to awards under the 2018 Plan expire or otherwise terminate without having been exercised or issued in full, are tendered to or withheld by the Registrant for payment of an exercise price or tax withholding obligations, or are
              forfeited to or repurchased by the Registrant due to failure vest, the shares of common stock subject to such awards will become available for issuance under the 2020 Plan.
(7)
Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $3.63, the weighted average price per share of outstanding stock option awards under the 2018 Plan as of December 3, 2020.
PART I
INFORMATION REQUIRED IN THE PROSPECTUS
The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (this "Registration Statement") in accordance with the provisions of Rule 428 under the
      Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as
      specified by Rule 428(b)(1) under the Securities Act.
PART II
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference.
Kinnate Biopharma Inc. (the "Registrant") hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the "Commission"):
(1) The Registrant's Prospectus dated December 2, 2020, filed with the Commission on December 3, 2020 pursuant to Rule 424(b) under the Securities Act, relating to the Registration Statement on Form S-1, as amended
      (File No. 333-250086), which contains the Registrant's audited financial statements for the latest fiscal year for which such statements have been filed; and
(2) The description of the Registrant's Common Stock contained in the Company's Registration Statement on Form 8-A (File No 001-39743) filed with the Commission on November 30, 2020, pursuant to Section 12(b) of the
      Securities Exchange Act of 1934, as amended (the "Exchange Act"), including any amendment or report filed for the purpose of updating such description.
All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to
      this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from
      the date of filing of such documents;
provided
,
however
, that documents or information deemed to have been furnished and not filed in accordance with the rules of the
      Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
      of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or
      superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 4.
Description of Securities.
Not applicable.
Item 5.
Interests of Named Experts and Counsel.
Not applicable.
Item 6.
Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation Law empowers a corporation to indemnify its directors and officers and to purchase insurance with respect to liability arising out of their capacity or status as
      directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed to be in our best interests, and, with respect to any criminal action, had no reasonable cause to believe the person's actions were
      unlawful. The Delaware General Corporation Law further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation's bylaws, any
      agreement, a vote of stockholders or otherwise. The certificate of incorporation of the registrant to be in effect upon the completion of this offering provides for the indemnification of the registrant's directors and officers to the fullest extent
      permitted under the Delaware General Corporation Law. In addition, the bylaws of the registrant to be in effect upon the completion of this offering require the registrant to fully indemnify any person who was or is a party or is threatened to be
      made a party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was a director or officer of the registrant, or is or was a
      director or officer of the registrant serving at the registrant's request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney's fees),
      judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, to the fullest extent permitted by applicable law.
Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or
      its stockholders for monetary damages for breach of fiduciary duty as a director, except (1) for any breach of the director's duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve
      intentional misconduct or a knowing violation of law, (3) for payments of unlawful dividends or unlawful stock repurchases or redemptions or (4) for any transaction from which the director derived an improper personal benefit. The registrant's
      certificate of incorporation to be in effect upon the completion of this offering provides that the registrant's directors shall not be personally liable to it or its stockholders for monetary damages for breach of fiduciary duty as a director and
      that if the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the registrant's directors shall be eliminated or limited to the fullest
      extent permitted by the Delaware General Corporation Law, as so amended.
Section 174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption
      may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes
      of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.
As permitted by the Delaware General Corporation Law, the registrant has entered into separate indemnification agreements with each of the registrant's directors and executive officers which would require the
      registrant, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors or executive officers.
The registrant expects to obtain and maintain insurance policies under which its directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in
      connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided by these policies
      may apply whether or not the registrant would have the power to indemnify such person against such liability under the provisions of the Delaware General Corporation Law.
These indemnification provisions and the indemnification agreements entered into between the registrant and the registrant's officers and directors may be sufficiently broad to permit indemnification of the
      registrant's officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act of 1933, as amended.
Item 7.
Exemption from Registration Claimed.
Not applicable.
Item 8.
Exhibits.
Incorporated by Reference
Exhibit
Number
Description
Form
File No.
Exhibit
Filing Date
4.2
Specimen common stock certificate of the Registrant
S-1/A
333-250086
4.2
11/30/2020
10.1
2018 Equity Incentive Plan, as amended, and form agreement thereunder
S-1
333-250086
10.2
11/13/2020
10.2
2020 Equity Incentive Plan, and form agreements thereunder
S-1/A
333-250086
10.3
11/30/2020
10.3
2020 Employee Stock Purchase Plan and form agreements thereunder
S-1/A
333-250086
10.4
11/30/2020
5.1
*
Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation
23.1
*
Consent of Independent Registered Public Accounting Firm
23.2
*
Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)
24.1
*
Power of Attorney (contained on signature page hereto)
*Filed herewith.
Item 9.
Undertakings.
A.
The undersigned Registrant hereby undertakes that:
(1)
It will file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
              in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered)
              and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no
              more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.
Provided, however
, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed
      with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
(2)
For the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
              that time shall be deemed to be the initial bona fide offering thereof.
(3)
It will remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
B.
The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where
              applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to
              the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
C.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions referenced in Item 6 of this Registration Statement,
              or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a
              claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or
              proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
              precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement
      to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California, on the 3
rd
day of December, 2020.
KINNATE BIOPHARMA INC.
By:
/s/ Nima Farzan
Nima Farzan
President and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Nima Farzan and Mark Meltz, and each of them, as such individual's true and lawful attorney in fact and agent with full power of
      substitution, for such individual in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in
      connection therewith, with the Securities and Exchange Commission, granting unto said attorney in fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
      therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney in fact, proxy and agent, or the individual's substitute, may lawfully do or cause to be done by virtue
      hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Nima Farzan
President, Chief Executive Officer and Director
(Principal Executive Officer)
December 3, 2020
Nima Farzan
/s/ Mark Meltz
Chief Operating Officer and General Counsel
(Principal Financial and Accounting Officer)
December 3, 2020
Mark Meltz
/s/ Dean Mitchell
Chair of the Board
December 3, 2020
Dean Mitchell
/s/ Melisa Epperly
Director
December 3, 2020
Melissa Epperly
/s/ Keith Flaherty, M.D.
Director
December 3, 2020
Keith Flaherty, M.D.
/s/ Carl Gordon, Ph.D.
Director
December 3, 2020
Carl Gordon, Ph.D.
/s/ Stephen Kaldor, Ph.D.
Director
December 3, 2020
Stephen Kaldor, Ph.D.
/s/ Michael Rome, Ph.D.
Director
December 3, 2020
Michael Rome, Ph.D.
/s/ Laurie Smaldone Alsup, M.D.
Director
December 3, 2020
Laurie Smaldone Alsup, M.D.
/s/ Jim Tananbaum, M.D.
Director
December 3, 2020
Jim Tananbaum M.D.